<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720629</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15033</org_study_id>
    <secondary_id>R01CA132197-06A2</secondary_id>
    <nct_id>NCT00720629</nct_id>
  </id_info>
  <brief_title>Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation</brief_title>
  <official_title>A Phase II Study of Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to test whether a new drug named visilizumab would decrease the
      severity of graft-versus-host disease in patients treated with a mismatched donor.
      Investigators planned to use visilizumab in combination with tacrolimus and methotrexate as
      the &quot;study treatment&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol plan was a two stage, controlled, phase II study to assess safety and compare
      the grade of acute graft-versus-host disease (GVHD) with visilizumab, or Anti-thymocyte
      Globulin (ATG) in combination with tacrolimus + methotrexate in patients at high risk of GVHD
      after transplant from unrelated donors mismatched for 1-2 alleles of any type at human
      leukocyte antigen (HLA) A, B, C and DRB1.

      The study design included two stages. The first stage of the trial was to enroll 15 patients
      on a single arm to be treated with &quot;study treatment&quot; (visilizumab, tacrolimus and
      methotrexate) to assess for treatment safety and exclude intolerable GVHD. The second stage
      of the trial was to include a random control group of patients treated with the current
      &quot;standard treatment&quot; (ATG, tacrolimus, and methotrexate) or &quot;study treatment&quot;. The purpose of
      this comparison was to determine if the &quot;study treatment&quot; visilizumab causes less severe side
      effects and if it is more potent in reducing graft-versus-host disease symptoms than the
      &quot;standard treatment&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade II-IV Acute Graft-versus-Host Disease (GVHD) Score at 100 Days</measure>
    <time_frame>100 days</time_frame>
    <description>Cumulative Incidence of Grade II-IV Acute GVHD Score at 100 Days. Investigators had planned to assess whether the grade of acute GVHD was decreased by visilizumab in combination with tacrolimus/methotrexate compared to standard treatment with thymoglobulin/tacrolimus/methotrexate after transplantation from unrelated mismatched donors, from day of transplant up to one year. Study was closed during the first treatment stage and did not proceed to the second stage treatment comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
Overall GVHD Grade: From Filipovich AH, Weisdorf D, Pavletic S, etal: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation 11:945-955 (2005). Grade I: Skin Stage 1-2, Liver Stage 0, Gut State 0; Grade II: Skin Stage 3 or, Liver Stage 1 or, Gut Stage 1; Grade II</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Epstein-Barr Virus (EBV) Reactivation</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants who reactivated EBV. Patients had their plasma tested once weekly using the TaqMan polymerase chain reaction (PCR) for quantitative determination of EBV-DNA for 6 weeks. Plasma levels &gt; 1000 copies per ml plasma were scored as positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Rituximab Response to Reactivated EBV Without PTLD</measure>
    <time_frame>100 days</time_frame>
    <description>Participants who developed plasma EBV-DNA of &gt;1000 copies/mL on any tests received rituximab.
Incidence of Rituximab Response: Reactivated EBV participants whose plasma titers cleared after rituximab, without post-transplant lymphoproliferative disorder (PTLD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At 2 years and 5 years</time_frame>
    <description>Median OS in days. Survival was measured from the time of transplant to the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of Visilizumab - Test 1</measure>
    <time_frame>At 1 - 2 hours</time_frame>
    <description>Mean Cmax (±SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of Visilizumab - Test 2</measure>
    <time_frame>Up to 205 hours</time_frame>
    <description>Mean terminal half-life (±SD)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>First Study Stage: Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visilizumab, Tacrolimus and Methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Study Stage: Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visilizumab</intervention_name>
    <description>3 mg/m^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).</description>
    <arm_group_label>First Study Stage: Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.</description>
    <arm_group_label>First Study Stage: Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>15 mg/m^2 intravenously (IV) on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.</description>
    <arm_group_label>First Study Stage: Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte globulin (ATG)</intervention_name>
    <description>1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.</description>
    <arm_group_label>Second Study Stage: Standard Treatment</arm_group_label>
    <other_name>Thymoglobulin-ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.</description>
    <arm_group_label>Second Study Stage: Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>15 mg/m^2 IV on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.</description>
    <arm_group_label>Second Study Stage: Standard Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One of the following diagnoses with histological confirmation by the Pathology
             Department at H. Lee Moffitt Cancer Center:

          -  Acute Lymphocytic Leukemia (ALL) in complete remission 1 (CR1) with t(9:22) or
             t(4:11), or any ALL beyond CR1

          -  Acute Myelogenous Leukemia (AML) with high risk cytogenetics in CR1 as defined by
             Bloomfield any AML beyond CR1

          -  Myelodysplastic Syndrome (MDS) with International Prognostic Scoring System (IPSS)
             score &gt; 1

          -  Chronic myelomonocytic leukemia (CMML)

          -  Chronic Myelogenous Leukemia (CML) with Imatinib-refractory chronic phase, or beyond
             chronic phase by morphology or cytogenetics

          -  Myelofibrosis

          -  Severe aplastic anemia

          -  Chemosensitive Non-Hodgkin's lymphoma and Hodgkin's disease that are not candidate to
             autologous transplant due to prior autologous transplantation

          -  Multiple Myeloma patient not candidate for autologous stem cell transplantation

          -  Karnofsky performance status ≥ 70% (adult)

          -  Normal organ and marrow function as defined below:

          -  Hepatic: Total bilirubin must be less than or equal to 2mg/dL (Gilbert and other
             syndromes with increased indirect bilirubin are allowed); serum transaminases must be
             less than two times the upper limit of normal

          -  Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) (corrected for Hgb),
             forced expiratory volume-one second (FEV1), forced vital capacity (FVC) must be
             greater than 50% predicted

          -  Cardiac: Left ventricular ejection fraction at rest must be greater than 50%

          -  Renal: Creatinine clearance (measured or calculated) must be equal or greater than 50
             ml/min/1.73m^2

        Exclusion Criteria:

          -  Anti thymocyte globulin (ATG) or anti T cell therapy in prior 45 days

          -  Splenectomized patients;

          -  A positive pregnancy test administered to all females of childbearing potential prior
             to allogeneic stem cell transplant

          -  Inability to comply with follow up as determined by the patient's physician

          -  HIV-I/II infection prior to hematopoietic stem cell (HSC) transplantation, confirmed
             by nucleic acid test (NAT)

          -  Uncontrolled bacterial or fungal infection

          -  History of documented invasive aspergillosis or cytomegalovirus (CMV) pneumonia

          -  Presence of any of the following comorbid conditions:

          -  History of myocardial infarction

          -  Congestive heart failure (even if symptomatically controlled)

          -  Peripheral vascular disease (including intermittent claudication or history of bypass
             for arterial insufficiency)

          -  Untreated thoracic or abdominal aneurysm (6cm or more)

          -  History of any cerebrovascular accident including transient ischemic attacks

          -  Dementia

          -  History of peptic ulcer disease requiring treatment

          -  Connective tissue/rheumatologic disorders

          -  Diabetes unless being managed with dietary changes only

          -  Hemiplegia/paraplegia

          -  History of solid tumor excluding skin or cervical carcinoma after curative resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lia Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/</url>
    <description>H. Lee Moffitt Cancer Center &amp; Research Institute</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2008</study_first_posted>
  <results_first_submitted>May 1, 2014</results_first_submitted>
  <results_first_submitted_qc>June 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>allogeneic transplant</keyword>
  <keyword>GVHD prevention</keyword>
  <keyword>unrelated donors</keyword>
  <keyword>mismatched unrelated donors</keyword>
  <keyword>hematological malignancies</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Aplastic Anemia</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at Moffitt Cancer Center between February 2008 and April 2010.</recruitment_details>
      <pre_assignment_details>The study was closed during the single-arm, first stage and did not proceed to the second stage comparison to antithymocyte globulin (ATG) in combination with tacrolimus/methotrexate as originally planned.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>First Study Stage: Study Treatment</title>
          <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>First Stage: Study Treatment. All participants.</population>
      <group_list>
        <group group_id="B1">
          <title>First Stage: Study Treatment</title>
          <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" lower_limit="23" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade II-IV Acute Graft-versus-Host Disease (GVHD) Score at 100 Days</title>
        <description>Cumulative Incidence of Grade II-IV Acute GVHD Score at 100 Days. Investigators had planned to assess whether the grade of acute GVHD was decreased by visilizumab in combination with tacrolimus/methotrexate compared to standard treatment with thymoglobulin/tacrolimus/methotrexate after transplantation from unrelated mismatched donors, from day of transplant up to one year. Study was closed during the first treatment stage and did not proceed to the second stage treatment comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
Overall GVHD Grade: From Filipovich AH, Weisdorf D, Pavletic S, etal: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation 11:945-955 (2005). Grade I: Skin Stage 1-2, Liver Stage 0, Gut State 0; Grade II: Skin Stage 3 or, Liver Stage 1 or, Gut Stage 1; Grade II</description>
        <time_frame>100 days</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>First Study Stage: Study Treatment</title>
            <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade II-IV Acute Graft-versus-Host Disease (GVHD) Score at 100 Days</title>
          <description>Cumulative Incidence of Grade II-IV Acute GVHD Score at 100 Days. Investigators had planned to assess whether the grade of acute GVHD was decreased by visilizumab in combination with tacrolimus/methotrexate compared to standard treatment with thymoglobulin/tacrolimus/methotrexate after transplantation from unrelated mismatched donors, from day of transplant up to one year. Study was closed during the first treatment stage and did not proceed to the second stage treatment comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
Overall GVHD Grade: From Filipovich AH, Weisdorf D, Pavletic S, etal: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation 11:945-955 (2005). Grade I: Skin Stage 1-2, Liver Stage 0, Gut State 0; Grade II: Skin Stage 3 or, Liver Stage 1 or, Gut Stage 1; Grade II</description>
          <population>All participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade II-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade I-II Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Epstein-Barr Virus (EBV) Reactivation</title>
        <description>Number of participants who reactivated EBV. Patients had their plasma tested once weekly using the TaqMan polymerase chain reaction (PCR) for quantitative determination of EBV-DNA for 6 weeks. Plasma levels &gt; 1000 copies per ml plasma were scored as positive.</description>
        <time_frame>3 months</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>First Study Stage: Study Treatment</title>
            <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Epstein-Barr Virus (EBV) Reactivation</title>
          <description>Number of participants who reactivated EBV. Patients had their plasma tested once weekly using the TaqMan polymerase chain reaction (PCR) for quantitative determination of EBV-DNA for 6 weeks. Plasma levels &gt; 1000 copies per ml plasma were scored as positive.</description>
          <population>All participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Rituximab Response to Reactivated EBV Without PTLD</title>
        <description>Participants who developed plasma EBV-DNA of &gt;1000 copies/mL on any tests received rituximab.
Incidence of Rituximab Response: Reactivated EBV participants whose plasma titers cleared after rituximab, without post-transplant lymphoproliferative disorder (PTLD).</description>
        <time_frame>100 days</time_frame>
        <population>Reactivated EBV participants</population>
        <group_list>
          <group group_id="O1">
            <title>First Study Stage: Study Treatment</title>
            <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Rituximab Response to Reactivated EBV Without PTLD</title>
          <description>Participants who developed plasma EBV-DNA of &gt;1000 copies/mL on any tests received rituximab.
Incidence of Rituximab Response: Reactivated EBV participants whose plasma titers cleared after rituximab, without post-transplant lymphoproliferative disorder (PTLD).</description>
          <population>Reactivated EBV participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Median OS in days. Survival was measured from the time of transplant to the time of death.</description>
        <time_frame>At 2 years and 5 years</time_frame>
        <population>Participants who had died by Year 2 and additional participants who had died by Year 5.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Year Analysis Group</title>
            <description>First Study Stage: Study Treatment. Visilizumab, Tacrolimus and Methotrexate.</description>
          </group>
          <group group_id="O2">
            <title>5 Year Analysis Group</title>
            <description>First Study Stage: Study Treatment. Visilizumab, Tacrolimus and Methotrexate.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Median OS in days. Survival was measured from the time of transplant to the time of death.</description>
          <population>Participants who had died by Year 2 and additional participants who had died by Year 5.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197" lower_limit="150" upper_limit="643"/>
                    <measurement group_id="O2" value="1803" lower_limit="1791" upper_limit="1816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics of Visilizumab - Test 1</title>
        <description>Mean Cmax (±SD)</description>
        <time_frame>At 1 - 2 hours</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>First Study Stage: Study Treatment</title>
            <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics of Visilizumab - Test 1</title>
          <description>Mean Cmax (±SD)</description>
          <population>All participants</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1564" spread="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics of Visilizumab - Test 2</title>
        <description>Mean terminal half-life (±SD)</description>
        <time_frame>Up to 205 hours</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>First Study Stage: Study Treatment</title>
            <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics of Visilizumab - Test 2</title>
          <description>Mean terminal half-life (±SD)</description>
          <population>All participants</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>The time of administration of visilizumab on Day 1 through Day 360. Per protocol, expected transplant/GVHD-related (other than serious) adverse event details were not tabulated in the same manner as serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>First Stage: Study Treatment</title>
          <description>Visilizumab, Tacrolimus and Methotrexate. All participants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GI - Colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infection - Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infection - Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other - pseudomonas pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study closed early during the first stage, did not proceed to the second stage comparison as planned. Investigators exercised right to close the study prematurely for lack of efficacy, although no protocol-defined end points had been met.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lia Perez, M.D.</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-7202</phone>
      <email>lia.perez@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

